Human clinical trials have demonstrated the efficacy of some FGF21-based analogs in the reduction of body weight [8] and treatment of dyslipidemia, NAFLD, and type 2 diabetes mellitus [11,12]. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.